Acquired resistance to a GPCR5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Jennifer DerrienSarah GastineauAntoine FrigoutNils GiordanoMia CherkaouiVictor GaboritRémi BoinonElise DouillardMagali DevicFlorence MagrangeasPhilippe MoreauStéphane MinvielleCyrille TouzeauEric LetouzéPublished in: Nature cancer (2023)
Bispecific antibodies targeting GPRC5D demonstrated promising efficacy in multiple myeloma, but acquired resistance usually occurs within a few months. Using a single-nucleus multi-omic strategy in three patients from the MYRACLE cohort (ClinicalTrials.gov registration: NCT03807128 ), we identified two resistance mechanisms, by bi-allelic genetic inactivation of GPRC5D or by long-range epigenetic silencing of its promoter and enhancer regions. Molecular profiling of target genes may help to guide the choice of immunotherapy and early detection of resistance in multiple myeloma.